Reappraisal of GIP Pharmacology for Metabolic Diseases.
Finan, Brian; Müller, Timo D; Clemmensen, Christoffer; Perez-Tilve, Diego; DiMarchi, Richard D; Tschöp, Matthias H.
Trends Mol Med
; 22(5): 359-376, 2016 05.
Artigo em Inglês | MEDLINE | ID: mdl-27038883
A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation.
Mapping interactions of gastric inhibitory polypeptide with GIPR N-terminus using NMR and molecular dynamics simulations.
Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models.
Pharmacological characterization of human incretin receptor missense variants.
Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice.
Nutritional strategy to prevent fatty liver and insulin resistance independent of obesity by reducing glucose-dependent insulinotropic polypeptide responses in mice.
DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.
GIP(3-30)NH is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.
Glucose-Dependent Insulinotropic Polypeptide Receptor Deficiency Leads to Impaired Bone Marrow Hematopoiesis.